The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes
Type 2 Diabetes
About this trial
This is an interventional treatment trial for Type 2 Diabetes focused on measuring type 2 diabetes, insulin, insulin injection, metformin, C-reactive protein, insulin sensitivity, glycemic control, inflammation
Eligibility Criteria
Inclusion Criteria: Men and women aged 18 to 79 Type 2 diabetes, treated only by diet or oral drugs other than metformin HbA1c greater than or equal to 7% and less than or equal to 10% C-reactive protein greater than or equal to 2 mg/L Exclusion Criteria: Baseline use of metformin or insulin Type 1 diabetes, history of ketoacidosis or positive anti-GAD antibody History of congestive heart failure requiring drug therapy Active liver disease Kidney impairment Recent initiation or change in dose of statins, fibric acid derivatives, angiotensin receptor blockers, nonsteroidal anti-inflammatory agents, or corticosteroids
Sites / Locations
- Brigham and Women's Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Placebo Comparator
Active Comparator
Active Comparator
Active Comparator
Placebo pill
Metformin Pill
Insulin Glargine plus placebo pill
Insulin Glargine plus metformin pill
Placebo pill
Metformin pill
Insulin glargine plus placebo pill
Insulin Glargine plus metformin pill